Sat, Apr 19, 2014, 2:59 PM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Alnylam Pharmaceuticals, Inc. Message Board

robert.vince 89 posts  |  Last Activity: Apr 9, 2014 11:47 AM Member since: Aug 30, 2012
  • Melbourne, Australia; Starpharma (ASX: SPL, OTCQX: SPHRY) today announced it has received the anticipated $4.7M of R&D tax incentive relating to FY13 expenditures, following the lodgement of the Company’s annual income tax return.

    The R&D tax refund relates to eligible Australian R&D expenditure, and previously announced overseas findings relating to Starpharma’s VivaGel®, and DEP™ docetaxel clinical programs.

    Commenting on the refund, Starpharma CEO Dr Jackie Fairley said:

    “The R&D tax incentive allows Starpharma to confidently advance development of its proprietary products including the clinical programs for VivaGel® and DEPTM docetaxel. In the case of DEP™ docetaxel, it supports the conduct of the clinical trial in Australia with the additional benefit that Australian patients will be the first in the world to have access to Starpharma’s improved version of the widely used cancer drug, docetaxel.”

  • Reply to

    CTSO or AEMD

    by gssolutions Mar 6, 2014 3:43 PM
    robert.vince robert.vince Mar 6, 2014 5:03 PM Flag

    I'd be happy if it were a photo finish (own both), as long as they set a quick pace ;)

  • Reply to

    Dr. Chan on "Re orders"..

    by agtjerry1 Mar 6, 2014 1:05 PM
    robert.vince robert.vince Mar 6, 2014 2:04 PM Flag

    What part of:
    ...............................".( Increasing orders and REORDERS )".........................
    didn't you get?

  • robert.vince robert.vince Mar 5, 2014 5:46 PM Flag

    Therapeutic Application and Patent Application

    The development of a therapeutic device that targets selective elimination of circulating beta-amyloid and tau is supported by the “peripheral sink” theory, which postulates that the reduction of these particles from systemic circulation promotes deplaquing from the brain. Thus, inhibiting the continued progression of neurodegenerative processes. Aethlon and ESI further disclosed the subsequent filing of a provisional patent entitled, “Brain Specific Exosome Based Diagnostics and Extracorporeal Therapies.”

  • robert.vince robert.vince Mar 5, 2014 5:46 PM Flag

    “With the exosome-based technologies developed by our group, we are at the verge of breakthroughs for the management and treatment of brain injuries and diseases that have been associated with disability and death,” stated Dr. Cicek Gercel-Taylor, Clinical Research Director at ESI.

    Circulating biomarkers have been proposed for the definitive diagnosis and monitoring treatment of brain injuries. The approach would enable diagnosing the condition, identifying processes that are difficult to image, monitoring responses to interventions, and predicting those who are at risk for long-term neurologic consequences. However, circulating biomarkers such as free protein and nucleic acids are extremely unstable in circulation, thus a high steady-state must be reached for detection, which is generally not observed except in severe cases. To circumvent these issues, exosome-associated biomarkers can be utilized as they are stable and detectable in the circulation.

    “An exosome-based liquid biopsy that could identify the early onset of Alzheimer’s disease or CTE in a living person may also unlock the ability to monitor disease progression and set the stage for new therapeutic advances, which could include Aethlon Medical therapeutic devices,” stated Jim Joyce, CEO of Aethlon Medical and Executive Chairman at Exosome Sciences.

  • robert.vince robert.vince Mar 5, 2014 5:46 PM Flag

    AD is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. Beta-amyloid plaques and neurofibrillary tangles have long been recognized as a common pathologic hallmark of AD. In 2010, it was estimated that 36 million people worldwide were living with AD.

    “This advancement represents a new paradigm for brain injuries. In addition to providing definitive diagnosis, the proteomic and transcriptomic characterization of exosomes isolated specifically from the brain will provide a window into the molecular mechanisms underlying acute and chronic brain injuries,” stated ESI Chief Scientific Officer, Dr. Douglas Taylor.

    As a result of the discoveries, brain-derived exosomes can be specifically isolated and the protein and RNA cargoes identified. In studies of brain tissue, specific RNAs have been associated with development of neurological disorders, contributing to the onset and progression of brain injuries. Exosomal RNA and protein cargoes represent surrogates to brain biopsies and have utility as stable, clinically accessible biomarkers for brain injury detection, stratification of patients and therapeutic outcomes.

  • robert.vince robert.vince Mar 5, 2014 5:45 PM Flag

    Here is the full press release:

    Aethlon Medical, Inc. (AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer’s Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.

    The research studies provided evidence that exosomes can serve as a “liquid biopsy” to diagnose neurologic conditions. While exosomes from the central nervous system have previously been identified in the cerebrospinal fluid, the Aethlon-ESI study identified exosomes carrying brain-specific markers tau, beta-amyloid, glycoprotein A2B5 and S100B protein in the peripheral circulation of affected individuals. The discoveries provide a basis for an exosome-based platform that could enable the simultaneous identification of multiple brain specific markers that are transported across the blood-brain barrier and into the circulatory system.

    CTE is a progressive degenerative disease, which at present can only be definitively diagnosed postmortem. CTE has been most commonly found at autopsy in former professional football players and has also been demonstrated to be prevalent in soldiers exposed to blast injury. The hallmark of CTE is the accumulation of tau, an abnormal protein that strangles brains cells in areas that control memory, emotions and other functions. TBI or repetitive brain trauma, including concussions and sub-concussive blows to the head contribute to the onset of CTE.

  • Whitefish, MT / March 5, 2014 / Some leading scientists are making strides like never before in research for debilitating and deadly diseases, such as Alzheimer’s Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Currently, people afflicted with these conditions have little hope to avert disease progression and, sadly, death. There is reason for optimism, though, with hundreds of organizations working on new treatments and diagnostics, including Neuralstem (NYSE MKT: CUR), Thermo Fisher Scientific (TMO) and Aethlon Medical (AEMD).

    CTE and TBI have been in news headlines in recent months with the National Football League settling a lawsuit with more than 4,500 former players and their families for $765 million in August and earmarking funds for research. CTE was been cited as the reason for high profile suicides of NFL payers Junior Seau, Dave Duerson, Andre Waters and more. Presently, definitive evidence of CTE can only be determined in an autopsy.

    Aethlon, and its diagnostic subsidiary Exosome Sciences, Inc., disclosed on Tuesday a discovery that may one day help diagnose CTE sooner, in addition to having serious implications for new diagnosis, monitoring tools and treatments in the hardest to treat neurodegenerative conditions of the brain. The companies reported that their research suggests brain-specific biomarkers of diseases and conditions, like AD, CTE and TBI, may be isolated in exosomes, tiny cell-derived vesicles that are found in essentially every bodily fluid. If additional research can build upon this new knowledge (for which Aethlon has already filed a patent), the impact on the industry could be tremendous and offer a new hope for millions of patients and their families worldwide.

  • robert.vince robert.vince Mar 5, 2014 5:43 PM Flag

    Therapeutic Application and Patent Application
    The development of a therapeutic device that targets selective elimination of circulating beta-amyloid and tau is supported by the “peripheral sink” theory, which postulates that the reduction of these particles from systemic circulation promotes deplaquing from the brain. Thus, inhibiting the continued progression of neurodegenerative processes. Aethlon and ESI further disclosed the subsequent filing of a provisional patent entitled, “Brain Specific Exosome Based Diagnostics and Extracorporeal Therapies.”

  • robert.vince robert.vince Mar 5, 2014 5:42 PM Flag

    “With the exosome-based technologies developed by our group, we are at the verge of breakthroughs for the management and treatment of brain injuries and diseases that have been associated with disability and death,” stated Dr. Cicek Gercel-Taylor, Clinical Research Director at ESI.
    Circulating biomarkers have been proposed for the definitive diagnosis and monitoring treatment of brain injuries. The approach would enable diagnosing the condition, identifying processes that are difficult to image, monitoring responses to interventions, and predicting those who are at risk for long-term neurologic consequences. However, circulating biomarkers such as free protein and nucleic acids are extremely unstable in circulation, thus a high steady-state must be reached for detection, which is generally not observed except in severe cases. To circumvent these issues, exosome-associated biomarkers can be utilized as they are stable and detectable in the circulation.
    “An exosome-based liquid biopsy that could identify the early onset of Alzheimer’s disease or CTE in a living person may also unlock the ability to monitor disease progression and set the stage for new therapeutic advances, which could include Aethlon Medical therapeutic devices,” stated Jim Joyce, CEO of Aethlon Medical and Executive Chairman at Exosome Sciences.

  • robert.vince robert.vince Mar 5, 2014 5:42 PM Flag

    The hallmark of CTE is the accumulation of tau, an abnormal protein that strangles brains cells in areas that control memory, emotions and other functions. TBI or repetitive brain trauma, including concussions and sub-concussive blows to the head contribute to the onset of CTE.
    AD is the most common form of dementia. There is no cure for the disease, which worsens as it progresses, and eventually leads to death. Beta-amyloid plaques and neurofibrillary tangles have long been recognized as a common pathologic hallmark of AD. In 2010, it was estimated that 36 million people worldwide were living with AD.
    “This advancement represents a new paradigm for brain injuries. In addition to providing definitive diagnosis, the proteomic and transcriptomic characterization of exosomes isolated specifically from the brain will provide a window into the molecular mechanisms underlying acute and chronic brain injuries,” stated ESI Chief Scientific Officer, Dr. Douglas Taylor.
    As a result of the discoveries, brain-derived exosomes can be specifically isolated and the protein and RNA cargoes identified. In studies of brain tissue, specific RNAs have been associated with development of neurological disorders, contributing to the onset and progression of brain injuries. Exosomal RNA and protein cargoes represent surrogates to brain biopsies and have utility as stable, clinically accessible biomarkers for brain injury detection, stratification of patients and therapeutic outcomes.

  • Discoveries Could Have Implications in the Diagnosis, Monitoring and Treatment of Alzheimer’s Disease, Chronic Traumatic Encephalopathy and Traumatic Brain Injury

    SAN DIEGO, March 5, 2014 /PRNewswire/ — Aethlon Medical, Inc. (AEMD), and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), announced today that its researchers have successfully isolated brain-specific biomarkers associated with a variety of neurodegenerative disorders. The discoveries could have implications in the diagnosis, monitoring and treatment of Alzheimer’s Disease (AD), Chronic Traumatic Encephalopathy (CTE) and Traumatic Brain Injury (TBI). Aethlon Medical develops therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions. ESI develops exosome-based solutions to diagnose and monitor acute and chronic conditions.
    Aethlon Hemopurifier.
    The research studies provided evidence that exosomes can serve as a “liquid biopsy” to diagnose neurologic conditions. While exosomes from the central nervous system have previously been identified in the cerebrospinal fluid, the Aethlon-ESI study identified exosomes carrying brain-specific markers tau, beta-amyloid, glycoprotein A2B5 and S100B protein in the peripheral circulation of affected individuals. The discoveries provide a basis for an exosome-based platform that could enable the simultaneous identification of multiple brain specific markers that are transported across the blood-brain barrier and into the circulatory system.
    CTE is a progressive degenerative disease, which at present can only be definitively diagnosed postmortem. CTE has been most commonly found at autopsy in former professional football players and has also been demonstrated to be prevalent in soldiers exposed to blast injury.

  • robert.vince robert.vince Mar 4, 2014 3:41 PM Flag

    KLH.V is stock traded on the Canadian (Vancouver) exchange. SBOTF trades in the US. I don't believe either has an advantage over the other, you buy whichever sells in your region. You could purchase KLH.V thru a canadian broker, but then there is just extra paperwork involved due to 2 countries being involved. When the stock was originally issued, it was issued as KLH.V only. They then did the paperwork required for getting them on the US pinks, and now they are working for an uplisting, hopefully soon.

  • Port Hueneme, CA (March 3, 2014) Stellar Biotechnologies, Inc. (“Stellar” or the “Company”) (OTCQB: SBOTF) (TSX-V: KLH) today announced the presentation of a poster at the Gordon Research Conference (GRC) on Marine Natural Products, being held March 2-7, 2014 in Ventura, California.

    The poster titled “Keyhole Limpet Hemocyanin (KLH): Protecting the Sole Marine Source of an Important Pharmaceutical Product” is authored by members of Stellar’s management team, Catherine Brisson, Ph.D., Chief Operating Officer, and Brandon Lincicum, Executive Director of Aquaculture and Facility Operations.

    The presentation recaps the importance of the KLH protein to the pharmaceutical industry’s development of new immunotherapies, and highlights the company’s manufacturing accomplishments that are aimed at sustainably meeting future biopharma need for KLH.

    “Stellar’s achievements in aquaculture science and KLH production will allow us to supply growing customer demand while averting depletion of the marine source of the molecule,” said Dr. Brisson. “We are showing that it is possible to deliver on both commercial and environmental fronts.”

    The focus of the GRC’s Marine Natural Products meeting is to present cutting edge research on the chemistry and biology of natural products from the marine environment.

    About Gordon Research Conferences (GRC)

    Gordon Research Conferences (GRC) is a non-profit organization managed by and for the benefit of the scientific community. The Gordon Research Conferences provide an international forum for the presentation and discussion of frontier research in the biological, chemical, and physical sciences, and their related technologies.

  • Reply to

    One less thing to worry about

    by robert.vince Feb 28, 2014 11:22 AM
    robert.vince robert.vince Feb 28, 2014 11:23 AM Flag

    The Settlement Agreement requires the Registrant to issue a total of 7,522,854 shares of common stock into an escrow and those shares will be released to Gemini ratably over a ten-month period. The shares are being issued upon partial exercise of the 2009 Warrant and 2010 Warrant as well as under a third warrant, issued by the Registrant to Gemini in 2008 (the "2008 Warrant"). No shares are to be issued as consideration for the alleged default under the Convertible Note or in consideration of the releases granted in the Settlement Agreement. In addition, the Registrant’s insurance company has agreed to pay Gemini $150,000. Upon completion of the share issuances, the 2008 Warrant, the 2009 Warrant and the 2010 Warrants will be canceled. In addition, under the Settlement Agreement, the Convertible Note (and any other agreement to pay Gemini or issue stock or anything else of value to Gemini) is extinguished and fully satisfied.

    As the Registrant previously had 6,359,999 shares of common stock reserved for issuance under the three Warrants described above, the settlement will increase the Registrant’s fully diluted shares outstanding by 1,162,855 shares.

    Upon the performance of the settlement terms described above, the Stipulation of Dismissal (filed as an Exhibit to this Current Report) will be filed with the Court, permanently terminating the litigation. The Settlement Agreement also provides for mutual and full releases of all other claims between the Registrant and Gemini.

    As a result of the Settlement Agreement, the Registrant has no pending or threatened litigation matters.

    The foregoing is a summary of the terms of the Settlement Agreement, Escrow Agreement and Stipulation of Dismissal, each of which is filed as an Exhibit to this Current Report. The Exhibits should be read in their entirety for a complete understanding of the terms of each Agreement.

  • robert.vince by robert.vince Feb 28, 2014 11:22 AM Flag

    On February 24, 2014, the Registrant entered into a Settlement Agreement and General Release (the “Settlement Agreement”) with Gemini Master Fund, Ltd., a Cayman Islands company ("Gemini") which, among other things, will result in the dismissal with prejudice of the complaint filed by Gemini against the Registrant on July 5, 2012 in the Supreme Court of the State of New York, County of New York, entitled Gemini Master Fund Ltd. v. Aethlon Medical, Inc., Index No. 652358/2012 (the "Complaint").

    In the Complaint, Gemini sought relief both in the form of money damages and delivery of shares of the Registrant’s common stock. The Complaint alleged, among other things, that the Registrant was in default of a convertible promissory note ("Convertible Note") originally issued to Gemini on February 12, 2010 by failing to pay the Convertible Note in full and by failing to honor certain requests by Gemini to convert the principal and interest under the Convertible Note into shares of the Registrant's common stock. The Complaint also alleged that the Registrant failed to issue shares upon the presentation of exercise notices under warrants originally issued to Gemini in 2009 and 2010 (respectively, the "2009 Warrant" and the "2010 Warrant").

    In the Complaint, Gemini alleged it was entitled to 22,389,382 shares of common stock upon conversion of the balance of the Convertible Note and Gemini alleged that it was entitled to receive 30,370,814 shares of common stock pursuant to the 2009 Warrant and the 2010 Warrant, for a combined sum of 52,760,196 common shares.

    In its response, the Registrant provided documentation that the Convertible Note had been paid in full in cash and accepted by Gemini prior to the filing of the Complaint. In addition, the Registrant had maintained on its books the total number of shares required to be issued under the 2009 Warrant, the 2010 Warrant and the 2008 Warrant (defined below) combined was 6,359,999 shares.

  • Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) will participate later today in the ASX Spotlight New York event.

    Starpharma is one of 15 ASX listed companies to be featured at the event, which is held annually to showcase emerging Australian companies before US institutional investors.

    CEO Dr Jackie Fairley will present at the event, which is in its seventh year and is attended by more than 240 investors.

    “Starpharma welcomes this opportunity to speak to the Company’s recent achievements and to build on an already strong and international institutional investor base,” said CEO Dr Jackie Fairley.

    There is an opportunity for one-on-one meetings in addition to the Company’s formal presentation, which will provide an overview of Starpharma’s business and portfolio including:
    Starpharma’s lead product, VivaGel® for the management and prevention of bacterial vaginosis, as a late-stage clinical asset.
    Two attractive commercial licenses for VivaGel®-coated condom: Ansell and Okamoto.
    Commencement of a Phase 1 clinical trial of DEP™ docetaxel and latest preclinical results for DEP™ oxaliplatin.
    An update on the agrochemical program, including internal development of a dendrimer-enhanced version of glyphosate (Roundup®).

  • The interim data presented evaluating ADCETRIS and bendamustine combination therapy in the salvage HL setting are encouraging, showing a complete remission rate of 77 percent, with another 15 percent of patients, who currently remain on treatment, achieving early partial remissions. In addition, a pooled analysis for the overall population in the AETHERA phase 3 clinical trial was presented, including demographic data, baseline disease characteristics and treatment exposure.
    Key points included: After a median of two cycles of therapy, 92 percent of patients evaluable for response (12 of 13 patients) achieved an objective response, including 77 percent (ten patients) with complete remissions and 15 percent (two patients) with partial remissions. At the time of analysis, the two patients with partial remissions had each received two cycles of therapy and treatment was ongoing. The most common adverse events were nausea (57 percent), rash (39 percent), fever (35 percent), fatigue (30 percent) and vomiting (30 percent).
    "We look forward to presenting efficacy and safety data from the AETHERA trial in the second half of 2014."

  • Aethlon Medical (AEMD) is an up and coming blood filtration device company making some pretty interesting products, nice to see DaVita getting involved with them at the ground floor.

  • robert.vince robert.vince Feb 26, 2014 8:47 AM Flag

    Aethlon further disclosed that the DCR agreement was entered into on a non-exclusive basis and is pending the completion of a definitive agreement, which will include a work order describing the full scope of services to be provided by DCR to Aethlon Medical.

    DaVita Clinical Research is a wholly owned subsidiary of DaVita HealthCare Partners (DVA), a Fortune 500 company and parent company of DaVita and HealthCare Partners. DaVita is a leading provider of kidney care in the United States and abroad, delivering dialysis services to patients with chronic kidney failure and end stage renal disease. As of December 31, 2013, DaVita operated or provided administrative services at 2,074 outpatient dialysis centers in the United States serving approximately 168,000 patients, and at 73 centers in ten countries outside of the United States. HealthCare Partners(R) manages and operates medical groups and affiliated physician networks in California, Nevada, Florida, Arizona and New Mexico in its pursuit to deliver excellent-quality health care in a dignified and compassionate manner. As of December 31, 2013, HealthCare Partners provided integrated care management for approximately 765,000 managed care patients.

ALNY
53.86-0.75(-1.37%)Apr 17 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.